Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14697
Abstract: To determine the effect of TTP399, a hepatoselective glucokinase activator, on the risk of ketoacidosis during insulin withdrawal in individuals with type 1 diabetes (T1D). read more here.
Keywords: insulin withdrawal; ketoacidosis insulin; glucokinase activator; hepatoselective glucokinase ... See more keywords